Congestive Heart Failure Treatment Devices Market To Reach $32.0 Billion By 2024 : Grand View Research, Inc.

The congestive heart failure (CHF) treatment devices market is expected to reach USD 32.0 billion by 2024, according to a new report by Grand View Research, Inc. The rising burden of CVDs is one of the prime factors responsible for lucrative growth of this vertical. Sedentary lifestyles, mental stress, and junk food consumption tendencies are the key factors responsible for development of CVDs.

Favorable reimbursement policies, such as the U.S. Medicare system, are observed to be a prime growth factor for this industry. Companies now provide new product platforms, which have reimbursement coverage that benefit the patient. The reimbursement can be availed for devices, such as Ventricular Assist Devices (VADs), Implantable Cardiovascular Defibrillators (ICDs), and pacemakers, which are used to treat CHF.

The industry participants are more focused on developing high-utility products, which can deliver personalized care. These advancements are improving the accuracy and provide additional capabilities to enhance the workflow and reduce the incidence of errors.

Browse full research report on Global Congestive Heart Failure (CHF) Treatment Devices Market: http://www.grandviewresearch.com/industry-analysis/bioactive-ingredients-market

Further key findings from the study suggest:

  • The market by product is segmented into VADs, Counter Pulsation Devices, ICDs, pacemakers, and cardiac resynchronization devices. The ICD segment consisting of two types, transvenous and subcutaneous, held a lucrative share in 2015, which was followed by the pacemaker’s segment. This can be attributed to the fact that defibrillators and pacemakers form the primary line of treatment administered for heart failure.
  • On the other hand, the VAD segment is anticipated to grow at a significant rate over the forecast period due to reimbursement coverage and technological advancements in VADs.
  • The VAD based on the site of implantation are categorized into Left Ventricular Assist Devices (LVAD) and Right Ventricular Assist Devices (RVAD). When the LVAD and RVAD are implanted together they are termed Biventricular Assist Devices (BIVAD).
  • North America dominated the overall market in terms of revenue share at over 40.0% in 2015; this can be attributed to the presence of a large population base suffering from CVDs coupled with a significant geriatric population base.
  • Asia-Pacific is anticipated to grow at a lucrative CAGR during the forecast period due to the increasing demand for these products. Furthermore, the rapidly improving healthcare infrastructure in the countries, such as India and Japan, also contribute toward the growth of this region.
  • Some of the players in this industry are Berlin Heart Inc., Medtronic, Boston Scientific, World Heart Corporation, Biotronik, Jarvik Heart, MicroMed Cardiovascular Inc., Teleflex Inc., and St. Jude Medical.
  • The market participants are actively involved in the improvement of the current product portfolio, in order to sustain their market position. Additionally, drug development and their market entry in the untapped nations are expected to propel market growth.

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/nutraceuticals-functional-foods-and-dietary-supplements 

Grand View Research has segmented the global CHF treatment devices market on the basis of product.
Global CHF Treatment Devices Market by Product (USD Million), 2013 - 2024
  • Ventricular Assist Devices (VADs)
    • LVAD
    • RVAD
    • BiVAD
  • Counter Pulsation Devices
  • Implantable Cardioverter Defibrillators
    • Transvenous ICD
    • Subcutaneous ICD
  • Pacemakers
    • Implantable
    • External
  • Cardiac Resynchronization therapy
    • Cardiac Resynchronization Therapy-Defibrillators (CRT-D)
    • Cardiac Resynchronization Therapy-Pacemakers (CRT-P)
CHF Treatment Devices Market by Region (USD Million), 2013 - 2024
  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
  • Asia Pacific
    • Japan
    • China
  • Latin America
    • Brazil
    • Mexico
  • MEA
    • South Africa
    • Saudi Arabia
Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-bioactive-ingredients-market   

About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc

For more information: www.grandviewresearch.com

Comments

Popular posts from this blog

The global vein illuminator market is expected to reach USD 358.5 million by 2024, according to a new report published by Grand View Research, Inc. The vein illuminator market is anticipated to witness a lucrative growth during the period 2016 to 2024. The factors contributing towards the growth of the market are the growing aging population and the efforts channelized towards improving patient satisfaction. Additionally, factors, such as the demand for technologically advanced medical equipment and the rising research and practical applications are expected to be opportunistic for the industry growth. However, the prevalence of traditional methods owing to the high costs of the vein illuminator devices is likely to hinder the growth of the market in the near future. The vein illuminator market is segmented on the basis of technology, application, end-user, and region. Based on technology, the market is further categorized into transillumination, infrared technology, and ultrasound. The near-infrared illumination technology is estimated to be the largest shareholder due to its ability to penetrate deep into the tissue, which makes it possible to visualize the vessels clearly. On the basis of application, the market is segmented into intravenous access and blood draw. The end-user segment comprises hospitals, rehabilitation facilities, blood donation camps, and academic institutions. The market for hospitals is expected to grow rapidly during the forecast period due to a surge in the demand for technologically advanced medical equipment. The market is also categorized into North America, Europe, Asia Pacific, MEA, and Latin America. Browse full research report on global Vein Illuminator Market: http://www.grandviewresearch.com/industry-analysis/vein-illuminator-market Further key findings from the study suggest: • In terms of market share, the North America vein illuminator market is expected to hold majority of the share in 2016. Factors resulting in the growth of this industry are the steady preference for highly-advanced medical devices by hospitals as well as the presence of several medical device manufacturing companies in the region. • The infrared illumination technology is estimated to lead the industry due to its deep penetration capability into thick tissues tohighlight the presence of vessels with increased clarity. Based on application, the segment for intravenous access is estimated to be the largest shareholder, followed by the blood draw segment. • The vein illuminator industry comprises several local as well as global players. Some prominent players in this industry include Accuvein, Inc., Christie Medical Holdings, Inc., Infrared Imaging Systems, Inc., Translite, LLC, and Venoscope, LLC,among others. In order to hold a major share in the industry, the companies are adopting both organic as well as inorganic strategies. The major strategies adopted by the companies are new product development, mergers, collaborations, partnerships, geographical expansions, and acquisitions. • The companies are also focusing on research and development activities in order to enhance their product portfolio. For instance, in September 2015, Accuvein, Inc., declared its 26th patent, which was issued by the United States Patent and Trademark office for their vein visualization system. Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/medical-devices Grand View Research has segmented the vein illuminator market on the basis of technology, application, and end-user application: Vein Illuminator Technology Outlook (Revenue, USD Million, 2013 - 2024) • Transillumination • Infrared technology • Others Vein Illuminator Application Outlook (Revenue, USD Million, 2013 - 2024) • Intravenous access • Blood draw • Others Vein Illuminator End-user Outlook (Revenue, USD Million, 2013 - 2024) • Hospitals • Blood donation camps • Academic institutions • Others Vein Illuminator Regional Outlook (Revenue, USD Million, 2013 - 2024) • North America • Europe • Asia Pacific • Latin America • MEA Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-vein-illuminator-market About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare. Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc For more information: www.grandviewresearch.com

Hyaluronic Acid Market Is Likely To Be Influenced By The Increase In Obesity Till 2024: Grand View Research, Inc.

Protein Purification & Isolation Market Is Predicted To Grow Swiftly Due To Increased Research In The Fields Of Biotechnology & Pharmaceuticals Till 2025: Grand View Research, Inc.